BD&L Summit for Life Sciences

Unlock the potential of a deal through optimizing business development activities and transactional excellence

San Francisco, CA, United States

The launch of our BD&L Summit for Life Sciences was so successful last year that the 2nd BD&L Summit returns to serve as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals. This year, the conference will go one step further and provide two tracks dedicated to the Legal/Transactions and Business Development areas.


  • New tracked program offers a selection of sessions so you can optimize your learning experience and focus on topics important to you and your company
  • Identify key business goals and map out a clear strategy for potential M&As with respect to tax inversion, consolidation, divestitures, and narrowing strategic focus to maximize portfolio value
  • Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
  • Gain valuable insight into the impact company culture can have on the success of integrating the workforce post-merger or acquisition


This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
  • Business Development/Corporate development
  • Mergers and Acquisitions
  • Licensing
  • Strategic Alliance/Alliance Management
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Due Diligence
  • External Innovation
  • Transactions
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Research and Development
  • Clinical Medicine
  • Clinical Operations
  • Life Cycle Management
This conference is also of interest to:
  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners


  • Neil Abdollahian, M.S., M.B.A., CIDARA THERAPEUTICS, Chief Business Officer
  • Philip Gutry, KRONOS BIO, Chief Business Officer
  • Christopher Haskell, Ph.D., BAYER, Vice President, Head Open Innovation Center - North America West
  • Olga Kay, J.D., Ph.D., ROCHE MOLECULAR SOLUTIONS, Senior IP Counsel
  • Sheldon L Koenig, MBA, PORTOLA PHARMACEUTICALS, Executive Vice President and Chief Commercial Officer
  • John Krayacich, LEO PHARMA, Senior Vice President and Head, Global Business Development
  • Jennifer Leeds, Ph.D., NOVARTIS, Executive Director, BD&L
  • Linus S Lin, Ph.D., ELI LILLY, Managing Director, Chorus
  • Angele Maki, Ph.D., ELI LILLY AND COMPANY, Vice President, Emerging Technology and Innovation
  • Antoun Nabhan, J.D., PEAR THERAPEUTICS, Vice President, Corporate Development
  • Jay Parrish, VIR BIOTECHNOLOGY, Chief Business Officer
  • Karah Parschauer, ULTRAGENYX, EVP, General Counsel
  • David Slack, MBA, VIRACTA THERAPEUTICS, Chief Business Officer

Please fill in your name and email to receive the Conference Agenda of this event.


Hyatt Centric Fisherman's Wharf
555 North Point Street, 94133
San Francisco, CA, USA

To make reservations guests can call 888-591-1234 and request the negotiated rate for this 2nd BD&L Summit. The group rate is available until February 18, 2020. Please book your room early, as rooms available at this rate are limited. To make reservations online click here.